Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching
Conclusion: In HCCs of 30 –50 mm, B-TACE should be preferred to cTACE, whereas in smaller nodules (#x3c;30 mm), cTACE can suffice in achieving a good CR rate. The statistically significant lower re-treatment rate of the B-TACE cohort after a single procedure reduced the risk of complications due to multiple TACE, which cou ld worsen the patient prognosis.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: research

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Conclusions: Ramucirumab provided a better survival benefit irrespective of BCLC stage and was well tolerated without compromising liver function during treatment.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: research

Role of Liver Resection for Hepatocellular Carcinoma with Vascular Invasion: Emerging Evidence from Western Countries
Patients with advanced hepatocellular carcinoma (HCC) with macrovascular invasion, that is, tumor thrombosis in the portal vein or hepatic vein, are generally considered not eligible for liver resection in Western countries, and only systemic therapy is recommended. However, there is a subgroup of patients who can survive long after surgical treatment despite having a very advanced stage of the disease. Some Asian surgical centers and a few Western surgical centers have been using surgery to treat BCLC stage C HCC as long as it is operable, and those centers have reported acceptable outcomes. In this issue ofLiver Cancer, ...
Source: Liver Cancer - July 8, 2021 Category: Cancer & Oncology Source Type: research

Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: research

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Conclusions: With prolonged follow-up, camrelizumab continues to demonstrate the durable response and long survival in pretreated advanced HCC patients with manageable toxicities, especially in those who continued the treatment beyond first RECIST-defined progression.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 30, 2021 Category: Cancer & Oncology Source Type: research

Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: research

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Conclusions: In a real-life Western scenario (mostly in a third-line setting), cabozantinib efficacy and safety data were comparable with those reported in its registration trial. Data regarding the prognostic factors might help in patient selection and design of clinical trials.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 15, 2021 Category: Cancer & Oncology Source Type: research

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Conclusions: IMbrave150 and GO30140 patients with unresectable HCC had varying baseline hepatic impairment and high enrollment from Asia. PK data demonstrated considerable exposure overlap across groups. Treatment was tolerable across groups. No need for dose adjustment based on mild or moderate hepatic impairment or region is recommended based on this analysis.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: research

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
Conclusion: The combined score including Wnt/ β-catenin activation, CPS of PD-L1, and degree of CD8+ TILs in HCC is informative for predicting the response to ICI in HCC cases. Constitutive activation of β-catenin can induce an immune cold phenotype with downregulation of immune-related genes, and immunohistochemistry-based evaluation is beneficial for identifying the subgroup that shows a good response to ICI.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 9, 2021 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2021;10:287 –288 (Source: Liver Cancer)
Source: Liver Cancer - June 8, 2021 Category: Cancer & Oncology Source Type: research

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
Conclusions: Obesity and heavy alcohol consumption increased the risk of HCC development after SVR.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 4, 2021 Category: Cancer & Oncology Source Type: research

Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 1, 2021 Category: Cancer & Oncology Source Type: research

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Conclusion: Cabozantinib treatment was effective, safe, and feasible in patients with advanced HCC in patients with compensated cirrhosis. Patients in the real-life setting had more advanced liver disease – in which 25% of patients were Child-Pugh B. However, OS in patients with Child-Pugh A cirrhosis was similar to that reported in the phase 3 trial (CELESTIAL).Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 1, 2021 Category: Cancer & Oncology Source Type: research

Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 25, 2021 Category: Cancer & Oncology Source Type: research

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a...
Source: Liver Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: research